Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1981 Nov;12(5):653-8.
doi: 10.1111/j.1365-2125.1981.tb01284.x.

Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy

Clonidine kinetics in man--evidence for dose dependency and changed pharmacokinetics during chronic therapy

M Frisk-Holmberg et al. Br J Clin Pharmacol. 1981 Nov.

Abstract

1 Clonidine kinetics were studied in 21 patients with essential hypertension. All received two bolus i.v. injections in the mean dose range of (0.78--3.36 micrograms kg-1) and one single oral dose (mean dose 1.7--2.3 micrograms kg-1) on separate occasions. The kinetics were also studied in some of these patients after multiple therapeutic oral dose (mean dose 1.1 or 1.9 micrograms kg-1) twice daily during a dosage interval after 6--12 months monotherapy with clonidine. The multiple oral dosage was based on the therapeutic response. 2 With increasing i.v. doses the rate constants (alpha, beta) decreased and the plasma clearance was reduced by 74% (9.94--2.61 ml min-1 kg-1) indicating dose-dependent kinetics. The volume of distribution (Vd beta) did not change with dose in contrast to the volume of the plasma compartment (Vc) which was increased at the highest doses. 3 The single oral dose kinetics agreed with the i.v. kinetics at comparable dose. The bioavailability was 90%. 4 During multiple oral dosing the elimination rate constants decreased compared to the single dose. The plasma clearance increased (7.18 ml min-1 kg-1) compared to the corresponding single dose (4.17 ml min-1 kg-1). The latter change was probably caused by the decrease in bioavailability to about 65%. 5 The pharmacodynamic properties of the drug could explain the changes in pharmacokinetics with increased dose and during multiple doses.

PubMed Disclaimer

References

    1. Arzneimittelforschung. 1969 Feb;19(2):169-76 - PubMed
    1. Life Sci. 1975 Aug 1;17(3):377-85 - PubMed
    1. Clin Pharmacol Ther. 1976 Jan;19(1):11-7 - PubMed
    1. Eur J Clin Pharmacol. 1977 Dec 28;12(6):463-9 - PubMed
    1. Arzneimittelforschung. 1978;28(2):255-9 - PubMed

Publication types

LinkOut - more resources